A study presented at the SNMMI Annual Meeting found that patients with rheumatoid arthritis, but not healthy controls, had localization of intravenous technetium-99m tilmanocept in inflamed joints without experiencing any adverse outcomes or drug reactions. The findings may prompt more studies aimed at determining the efficacy of intravenous Tc-99m tilmanocept imaging in guiding RA treatment, said researcher Arash Kardan.
Rheumatoid arthritis monitored using intravenous Tc-99m tilmanocept
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.